InterVenn Biosciences

14 articles about InterVenn Biosciences

• InterVenn Biosciences Announces the Publication of Early Detection of Advanced Adenoma and Colorectal Cancer in Gastroenterology, the Flagship Journal of the American Gastroenterological Association

  10/13/2023

  InterVenn Biosciences, a life sciences company pioneering glycoproteomics, announced the publication of their discovery work in Advanced Adenoma and Colorectal Cancer early disease detection in the flagship journal of the American Gastroenterological Association, Gastroenterology.

• InterVenn Biosciences Welcomes Accomplished Diagnostics Executive Joshua Stahl as CEO

  9/27/2023

  InterVenn Biosciences, the life sciences company pioneering glycoproteomic-based diagnostics, announced that Joshua Stahl has been appointed as Chief Executive Officer to guide the company’s next phase of commercial growth.

• InterVenn Biosciences to Present Clinical Data on Circulating Serum Glycoproteins for Unprecedented Pre-Cancer Detection as “Poster of Distinction” at Digestive Disease Week 2023

  4/19/2023

  InterVenn Biosciences today announced new clinical data that demonstrates the power of InterVenn’s proprietary biomarker discovery platform, GlycoVision™ , to detect advanced adenomas (AA) and colorectal cancer (CRC).

• InterVenn Biosciences Enters Next Stage with Senior Management Team Updates Focused on Commercialization

  1/5/2023

  InterVenn Biosciences today announced changes to its senior management team to support its commercialization execution.

• InterVenn Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023

  1/3/2023

  InterVenn Biosciences today announced that senior management will present at the J.P. Morgan 41st annual Healthcare Conference on January 11, 2023 at 8:30 a.m. Pacific.

• InterVenn Biosciences to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum

  11/10/2022

  InterVenn Biosciences today announced Company management will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on November 17, 2022 at 2:30 p.m. Eastern Time.

• Erwin Estigarribia is Appointed President and Chief Operating Officer of InterVenn Biosciences

  10/26/2022

  InterVenn Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, today announced that Erwin Estigarribia has been appointed President and Chief Operating Officer, effective immediately.

• InterVenn Biosciences Co-Founder Carolyn Bertozzi Awarded Nobel Prize in Chemistry

  10/5/2022

  InterVenn Biosciences announced that its co-founder Carolyn Bertozzi, Ph.D., has been awarded the 2022 Nobel Prize in chemistry.

• InterVenn Biosciences Expands Board of Directors with Dr. Jason Myers and Carol Berry to Support Next Phase of Growth

  10/4/2022

  InterVenn Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, announced the appointment of Jason Myers, Ph.D., and Carol Berry to the company’s Board of Directors.

• InterVenn Biosciences to Present at the 20th Annual Morgan Stanley Global Healthcare Conference

  9/6/2022

  InterVenn Biosciences, the leader in glycoproteomics, today announced Aldo Carrascoso, Co-Founder and CEO, and Erwin Estigarribia, COO, will present at the 20th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2022 in New York, NY.

• InterVenn Biosciences Announces Start of Enrollment in Colonoscopy Study

  8/2/2022

  InterVenn® Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, today announced the start of enrollment in its prospective cohort study for early detection of colorectal cancer and adenomas.

• InterVenn Expands Global Presence to Drive the Potential of Glycoproteomics to Improve Patient Outcomes

  7/21/2022

  InterVenn Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, today announced that it has expanded its global presence with the opening of multiple new locations in Asia-Pacific and North America.

• InterVenn Biosciences Announces New Data Validating the Clinical Performance of DAWN™ IO Melanoma as a Novel Liquid Biopsy Test to Improve Assessment of Benefit to Cancer Patients

  6/2/2022

  DAWN™ IO Melanoma is commercially available as a unique glycoproteomics laboratory-developed test (LDT) that aids Oncologists in planning treatment for Melanoma.

• InterVenn Biosciences Joins the WIN and FNIH Biomarker Consortiums to Introduce a Glycoproteomic Option for Liquid Biopsies

  6/1/2022

  InterVenn® Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, today announced that it has joined the Worldwide Innovative Network (WIN) Consortium and the Foundation for the National Institutes of Health’s Biomarker Consortium.